Cargando…

Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19

Detalles Bibliográficos
Autores principales:	Stanne, Tara M., Pedersen, Annie, Gisslén, Magnus, Jern, Christina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2021
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8163729/ https://www.ncbi.nlm.nih.gov/pubmed/34102452 http://dx.doi.org/10.1016/j.thromres.2021.05.016

Ejemplares similares

Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study
por: van Haaps, Thijs F., et al.
Publicado: (2021)

Role of upfront CT pulmonary angiography at admission in COVID-19 patients
por: Jalaber, Carole, et al.
Publicado: (2020)

Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era
por: Qin, Wei, et al.
Publicado: (2021)

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
por: Daughety, Molly M., et al.
Publicado: (2020)

Early thromboembolic events in hospitalized COVID-19 patients
por: Rosen, Raphael J.
Publicado: (2020)

Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia
por: Hsu, Andrew, et al.
Publicado: (2020)

Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection
por: Bourguignon, Alex, et al.
Publicado: (2020)

COVID-19 coagulopathy and thrombosis: Analysis of hospital protocols in response to the rapidly evolving pandemic
por: Parks, Anna L., et al.
Publicado: (2020)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Effect of government interventions to contain the COVID-19 pandemic on incidence of pulmonary embolism - A Danish nationwide register-based cohort study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2021)

Hospitalizations, resource use and outcomes of acute pulmonary embolism in Germany during the Covid-19 pandemic
por: Husser, Daniela, et al.
Publicado: (2021)

D-dimer driven deep vein thrombosis prophylaxis strategy for hospitalized patients with COVID-19
por: Stawiarski, Kristin, et al.
Publicado: (2021)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19
por: Choi, Justin J., et al.
Publicado: (2020)

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom
por: Thomas, W., et al.
Publicado: (2020)

Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy
por: Lawlor, Matthew, et al.
Publicado: (2021)

Don't let D-dimer fool you: Elevated D-dimer plasma levels should not imply ‘hyperfibrinolysis’
por: Hardy, M., et al.
Publicado: (2022)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Incidence of venous thromboembolic events in COVID-19 patients after hospital discharge: A systematic review and meta-analysis
por: Zuin, Marco, et al.
Publicado: (2022)

In-hospital fatality and venous thromboembolism during the first and second COVID-19 waves at a center opting for standard-dose thromboprophylaxis
por: Mumoli, Nicola, et al.
Publicado: (2021)

Correlation of indirect markers of hypercoagulability with thromboelastography in severe coronavirus 2019
por: Hightower, Stephanie, et al.
Publicado: (2020)

Early effects of unfractionated heparin on clinical and radiological signs and D-dimer levels in patients with COVID-19 associated pulmonary embolism: An observational cohort study
Publicado: (2021)

Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units
por: Doyle, Andrew J., et al.
Publicado: (2020)

Serial fibrin monomer and D-dimer plasma levels measurements can capture thrombotic complications in critically ill COVID-19 patients: A prospective observational study
por: Hardy, M., et al.
Publicado: (2023)

Comparison of IMPROVE, modified IMPROVE, IMPROVEDD, Padua and CHA2DS2-VASC risk scores for venous and arterial thrombotic events prediction in hospitalized COVID-19 patients
por: Lucijanic, Marko, et al.
Publicado: (2022)

High mobility group box 1 (HMGB 1): a new protein in the pathogenesis of ENT inflammatory and infectious diseases
por: PASSALI, D., et al.
Publicado: (2012)

Role of H.E.L.P.-apheresis in the treatment of sudden sensorineural hearing loss in a group of 230 patients
por: BIANCHIN, G., et al.
Publicado: (2011)

Systemic thromboemboli in patients with Covid-19 may result from paradoxical embolization
por: Rajendram, Rajkumar, et al.
Publicado: (2020)

Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients
por: van Veenendaal, Nadine, et al.
Publicado: (2020)

More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism
por: van Dam, L.F., et al.
Publicado: (2020)

Portal vein thrombosis in a patient with COVID-19
por: Franco-Moreno, A., et al.
Publicado: (2020)

The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?
por: Previtali, Giulia, et al.
Publicado: (2020)

Demystifying pulmonary vascular complications in severe coronavirus disease-19 pneumonia (COVID-19) in the light of clinico-radiologic-pathologic correlation
por: Parry, Arshed Hussain, et al.
Publicado: (2020)

Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit
por: Vlot, E.A., et al.
Publicado: (2020)

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?
por: Siguret, Virginie, et al.
Publicado: (2020)

Covid-19 associated autoimmune thrombotic thrombocytopenic purpura: Report of a case
por: Hindilerden, Fehmi, et al.
Publicado: (2020)

Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study
por: Hardy, Michaël, et al.
Publicado: (2021)

Major cardiovascular events in patients with Coronavirus Disease 2019: Experience of a cardiovascular department of Northern Italy()
por: Bellosta, Raffaello, et al.
Publicado: (2021)

In situ pulmonary thrombosis in patients with COVID-19 pneumonia: different phenotypes may exist
por: Wang, Lan, et al.
Publicado: (2020)

The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort
por: Lynn, Lei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gqtto7h59dplv8f6o27g2o62vv